Cargando…

Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors

To determine visual outcome including the occurrence of radiation induced optic neuropathy (RION) as well as tumor control after fractionated stereotactic radiation therapy (FSRT) of benign anterior skull base meningiomas or pituitary adenomas. Thirty-nine patients treated with FSRT for anterior sku...

Descripción completa

Detalles Bibliográficos
Autores principales: Astradsson, Arnar, Wiencke, Anne Katrine, Munck af Rosenschold, Per, Engelholm, Svend-Aage, Ohlhues, Lars, Roed, Henrik, Juhler, Marianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023078/
https://www.ncbi.nlm.nih.gov/pubmed/24532196
http://dx.doi.org/10.1007/s11060-014-1399-0
_version_ 1782316506380500992
author Astradsson, Arnar
Wiencke, Anne Katrine
Munck af Rosenschold, Per
Engelholm, Svend-Aage
Ohlhues, Lars
Roed, Henrik
Juhler, Marianne
author_facet Astradsson, Arnar
Wiencke, Anne Katrine
Munck af Rosenschold, Per
Engelholm, Svend-Aage
Ohlhues, Lars
Roed, Henrik
Juhler, Marianne
author_sort Astradsson, Arnar
collection PubMed
description To determine visual outcome including the occurrence of radiation induced optic neuropathy (RION) as well as tumor control after fractionated stereotactic radiation therapy (FSRT) of benign anterior skull base meningiomas or pituitary adenomas. Thirty-nine patients treated with FSRT for anterior skull base meningiomas and 55 patients treated with FSRT for pituitary adenomas between January 1999 and December 2009 with at least 2 years follow-up were included. Patients were followed up prospectively with magnetic resonance imaging scans, visual acuity and visual field examinations. RION was found in four (10 %) patients with anterior skull base meningiomas and seven patients (13 %) with pituitary adenomas. The five-year actuarial freedom from 25 % RION visual field loss was 94 % following FSRT. Actuarial 2-, 5- and 10-year tumor control rates were 100, 88.4 and 64.5 % for anterior skull base meningiomas and 100, 98.2 and 94.9 % for pituitary adenomas, respectively. Patients with an impaired visual field function pre-FSRT were more likely to experience worsened function (p = 0.016). We found that RION, was a relatively uncommon event, in a large prospective cohort of patients that were systematically monitored following FSRT of benign anterior skull base tumors. Long term tumor control was favorable, especially for pituitary adenomas.
format Online
Article
Text
id pubmed-4023078
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-40230782014-05-16 Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors Astradsson, Arnar Wiencke, Anne Katrine Munck af Rosenschold, Per Engelholm, Svend-Aage Ohlhues, Lars Roed, Henrik Juhler, Marianne J Neurooncol Clinical Study To determine visual outcome including the occurrence of radiation induced optic neuropathy (RION) as well as tumor control after fractionated stereotactic radiation therapy (FSRT) of benign anterior skull base meningiomas or pituitary adenomas. Thirty-nine patients treated with FSRT for anterior skull base meningiomas and 55 patients treated with FSRT for pituitary adenomas between January 1999 and December 2009 with at least 2 years follow-up were included. Patients were followed up prospectively with magnetic resonance imaging scans, visual acuity and visual field examinations. RION was found in four (10 %) patients with anterior skull base meningiomas and seven patients (13 %) with pituitary adenomas. The five-year actuarial freedom from 25 % RION visual field loss was 94 % following FSRT. Actuarial 2-, 5- and 10-year tumor control rates were 100, 88.4 and 64.5 % for anterior skull base meningiomas and 100, 98.2 and 94.9 % for pituitary adenomas, respectively. Patients with an impaired visual field function pre-FSRT were more likely to experience worsened function (p = 0.016). We found that RION, was a relatively uncommon event, in a large prospective cohort of patients that were systematically monitored following FSRT of benign anterior skull base tumors. Long term tumor control was favorable, especially for pituitary adenomas. Springer US 2014-02-15 2014 /pmc/articles/PMC4023078/ /pubmed/24532196 http://dx.doi.org/10.1007/s11060-014-1399-0 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Clinical Study
Astradsson, Arnar
Wiencke, Anne Katrine
Munck af Rosenschold, Per
Engelholm, Svend-Aage
Ohlhues, Lars
Roed, Henrik
Juhler, Marianne
Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors
title Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors
title_full Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors
title_fullStr Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors
title_full_unstemmed Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors
title_short Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors
title_sort visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023078/
https://www.ncbi.nlm.nih.gov/pubmed/24532196
http://dx.doi.org/10.1007/s11060-014-1399-0
work_keys_str_mv AT astradssonarnar visualoutcomeafterfractionatedstereotacticradiationtherapyofbenignanteriorskullbasetumors
AT wienckeannekatrine visualoutcomeafterfractionatedstereotacticradiationtherapyofbenignanteriorskullbasetumors
AT munckafrosenscholdper visualoutcomeafterfractionatedstereotacticradiationtherapyofbenignanteriorskullbasetumors
AT engelholmsvendaage visualoutcomeafterfractionatedstereotacticradiationtherapyofbenignanteriorskullbasetumors
AT ohlhueslars visualoutcomeafterfractionatedstereotacticradiationtherapyofbenignanteriorskullbasetumors
AT roedhenrik visualoutcomeafterfractionatedstereotacticradiationtherapyofbenignanteriorskullbasetumors
AT juhlermarianne visualoutcomeafterfractionatedstereotacticradiationtherapyofbenignanteriorskullbasetumors